Top 5 Biotech Stocks to Buy According to Jeremy Green’s Redmile Group

Page 5 of 5

1. Fate Therapeutics, Inc. (NASDAQ:FATE)

Redmile Group’s Stake Value: $768 million

Percentage of Redmile Group’s 13F Portfolio: 13.39%

Number of Hedge Fund Holders: 36                 

Fate Therapeutics, Inc. (NASDAQ:FATE) is a biopharmaceutical clinical-stage company that develops new and advanced cellular immunotherapies to treat cancer and immune disorders. The firm works to produce improved cell therapies by using its proprietary iPSC product platform.

On November 8, Citi analyst Yigal Nochomovitz upgraded the rating from Neutral to Buy on Fate Therapeutics, Inc. (NASDAQ:FATE) stock and lowered the price target from $94 to $87.

According to Insider Monkey’s database of 867 funds, 36 hedge funds have stakes in Fate Therapeutics, Inc. (NASDAQ:FATE) worth $2.1 billion at the end of the third quarter, down from 40 funds having stakes worth $2.767 billion in the last quarter.

Fate Therapeutics, Inc. (NASDAQ:FATE) is the biggest investment in Redmile Group’s portfolio. As of the end of the third quarter, the fund owned 12.96 million shares in the company worth $768 million, comprising 13.39% of the portfolio.

You can also take a look at the Top 10 Stock Picks of Joe Huber’s Huber Capital Management and Top 10 Stock Picks of Leon Lowenstein’s Lionstone Capital Management.

Page 5 of 5